Please login to the form below

Not currently logged in
Email:
Password:

Vaccine development

This page shows the latest Vaccine development news and features for those working in and with pharma, biotech and healthcare.

Takeda gets FDA fast-track status for Zika vaccine

Takeda gets FDA fast-track status for Zika vaccine

Takeda is thought to be furthest ahead in development with TAK-426 - a purified, inactivated, alum-adjuvanted, whole Zika virus vaccine candidate - after Sanofi Pasteur dropped its development programme for another ... Laurence De Moerlooze, Takeda’s

Latest news

  • Janssen’s quest to prevent diseases taking hold Janssen’s quest to prevent diseases taking hold

    This potent test bed has helped with development of its promising mosaic-based vaccine regimen for HIV which was reported at the 9th International Aids Society Conference on HIV Science in ... Its continuing work on Ebola has seen laboratory results that

  • Sanofi and Merck & Co finalise vaccine alliance split Sanofi and Merck & Co finalise vaccine alliance split

    The former partners will now separately pursue vaccine development strategies for European patients, integrating their respective pipeline pursuits and products from the venture into their primary vaccines portfolios. ... The French company also began

  • Efficacy trials get underway for HIV vaccine in South Africa Efficacy trials get underway for HIV vaccine in South Africa

    The safety of the vaccine was shown in a smaller study (HVTN 100). ... The HIV Vaccine Trials Network - part of the P5 public-private partnership behind the vaccine's development along with the organiser of the trial - has said that it believes that if

  • Takeda starts trial of norovirus vaccine Takeda starts trial of norovirus vaccine

    Takeda starts trial of norovirus vaccine. If approved the drug is anticipated to surpass sales of GSK’ s Rotarix vaccine. ... Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the

  • Malaria vaccine is first to provide 'sustained protection' Malaria vaccine is first to provide 'sustained protection'

    A malaria vaccine in development by US biopharma company Sanaria has demonstrated sustained protection against the parasite, according to the results of a clinical trial. ... The vaccine is based on inactivated Plasmodium falciparum sporozoites, a key

More from news
Approximately 0 fully matching, plus 117 partially matching documents found.

Latest Intelligence

  • Immunisation politicised Immunisation politicised

    Feminists pointed to the gendered nature of the vaccine, raising questions as to why only women appeared to have been considered in vaccine development, much like they have historically been in ... While the vaccine remained freely available, it was not

  • Deal Watch September 2016 Deal Watch September 2016

    up. Turning to the battle against the Zika virus, BARDA announced three more grants for vaccine development to Takeda (up to $312m), Moderna [up to $125m] and Sanofi ($43.2m). ... In a similar vein Sanofi will receive $43.2m in funding for the mid stage

  • Deal Watch December 2015 Deal Watch December 2015

    409. Kyorin (JP). BMS. Collaboration, licence. Discovery, development and commercialisation of FPR 2 agonists for undisclosed indication. ... 200. Bavarian Nordic (DK). Janssen. Collaboration, licence. Vaccine platform technology for development of

  • Pharma deals during January 2013 Pharma deals during January 2013

    This deal is for technology development and carries a $5m non-refundable payment. ... GSK. JV. Combination paediatrics vaccines. Terminations. Although the active development for Cytos'NIC 002 therapeutic vaccine for smoking cessation had ceased some

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... LigoCyte has a number of vaccine products in development, including its lead candidate, which is in phase I/II vaccine to prevent norovirus

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • McCann Health appoints Daniel Carucci as global medical director McCann Health appoints Daniel Carucci as global medical director

    Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health

  • Sanofi names CSO Gary Nabel to Ebola role Sanofi names CSO Gary Nabel to Ebola role

    Elias Zerhouni, president of Sanofi global research and development, said: “ Given his past experience in public health epidemics as director of the NIH vaccine research centre and his leadership in developing ... He is working with other organisations,

  • Takeda appoints head of vaccines development Takeda appoints head of vaccines development

    Boslego will be responsible for accelerating global vaccine development activities with a focus on lead development programmes for dengue, norovirus and seasonal influenza. ... development organisation and advanced vaccine development against illnesses

  • Sanofi appoints NIH’s Gary Nabel as chief scientific officer Sanofi appoints NIH’s Gary Nabel as chief scientific officer

    Sanofi appoints NIH’ s Gary Nabel as chief scientific officer. He previously headed vaccine research centre of the US National Institute of Allergy and Infectious Diseases. ... During this period, he provided overall direction of the VRC, including the

  • Peter Chambre joins cancer vaccine biotech Immatics Peter Chambre joins cancer vaccine biotech Immatics

    Peter Chambre joins cancer vaccine biotech Immatics. He replaces Thomas Widmann as chair of the board. ... With IMA901, Immatics' lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical

More from appointments
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics